Full text is available at the source.
Abstract
Baseline monocyte glucose-dependent insulinotropic polypeptide receptor (GIPR) mRNA expression may be linked to changes in body weight and the fibrosis-4 (FIB-4) index in patients with type 2 diabetes after switching treatments.
- Tirzepatide is associated with improvements in body weight and glycemic control in type 2 diabetes patients.
- Inter-individual differences in response to tirzepatide after switching from GLP-1 receptor agonists are not well understood.
- Higher levels of baseline GIPR mRNA expression could correlate with greater weight loss.
- Changes in the FIB-4 index may also be influenced by baseline GIPR mRNA levels.
Simplified